Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

INTRODUCTION/OBJECTIVES: To describe abemaciclib use in patients with hormone receptor-positive, human epidermal growth factor receptor-negative (HR+/HER2−) metastatic breast cancer (mBC) who participated in the Named Patient Use program (NPU) in Spain. MATERIAL AND METHODS: This retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanch, Salvador, Gil-Gil, Juan Miguel, Arumí, Miriam, Aguirre, Elena, Seguí, Miguel Ángel, Atienza, Manuel, Díaz-Cerezo, Silvia, Molero, Alberto, Cervera, José Manuel, Gavilá, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462534/
https://www.ncbi.nlm.nih.gov/pubmed/37029241
http://dx.doi.org/10.1007/s12094-023-03159-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462534/
https://www.ncbi.nlm.nih.gov/pubmed/37029241
http://dx.doi.org/10.1007/s12094-023-03159-9

Ejemplares similares